Possible explanation of rare prothrombotic events with the AstraZeneca vaccine in Europe


There are press releases and communiqués, though no published studies, stating the following: In response to
reports that emerged after a few recipients of the AstraZeneca COVID-19 vaccine (AZ1222) [based on the
recombinant adenovirus vector encoding the SARS-CoV-2 spike (S) glycoprotein] developed unusual thrombotic
events and thrombocytopenia, a group of researchers at the University of Greifswald in Germany, together with a
similar team at the University Hospital of Vienna (Austria), McMaster University (Canada), and the Paul Ehrlich
Institute (Germany), investigated whether these patients might have a prothrombotic disorder caused by platelet
activation due to the presence of antibodies targeting platelet proteins. A similar mechanism has been found to be
caused by heparin or, sometimes, by environmental triggers.

As a result of international collaboration between scientists, doctors, regulatory authorities, physicians, and
consenting patients in a brief three-day period, it was possible to:

• Identify a possible mechanism by which the vaccine induced severe thrombotic complications;
• Identify a widely available diagnostic test;
• Develop a confirmatory test that appears to be highly sensitive and specific (despite possible limitations of
the sample size);
• Identify a treatment that can quickly address the catastrophic prothrombotic mechanism: IV Ig (Intravenous
Immunoglobulin) is an effective treatment against HIT (Heparin-induced thromboducedcytopenia), which is
similar, in clinical and laboratory settings, to the complications found in connection with the vaccine. This
product, IV Ig, is approved and available in most hospitals.

Researchers even proposed a name for this syndrome, namely, VIPIT: Virus/Vaccine Induced Prothrombotic Immune

Source: University of Greifswald Medical School. University of Greifswald Medical School Reports Breakthrough in SARS-CoV-2
Vaccination-Related Thrombotic Complications. 2/22/2021.

Link to statement: https://gth-online.org/wp-content/uploads/2021/03/GTH_Stellungnahme_AstraZeneca_engl._3_22_2021.pdf

  • Share:

Related News